Stockpolly
Search
PFE · NYSE · Drug Manufacturers - General

Pfizer

Developer of prescription medicines and vaccines across oncology, internal medicine, immunology and infectious disease.

$27.95
After-hours close−0.01 (−0.04%)
At close$27.96(−0.21%)
Loading prices…

Something off on this page? Send us feedback.

Profile

Pfizer Inc.PFEHealth Care

Develops and sells prescription medicines and vaccines across internal medicine, oncology, immunology, rare disease and infectious disease, supported by global research, manufacturing and commercial operations. Biopharma is the sole reportable segment, and results depend on product approvals, payer access and replacing revenue as major medicines lose market exclusivity.

Discovers, develops, manufactures and sells prescription medicines and vaccines across internal medicine, oncology, vaccines, inflammation and immunology, rare disease and hospital care. Key franchises include the Eliquis anticoagulant, Prevnar pneumococcal vaccines, Vyndaqel cardiomyopathy treatments, Ibrance and Seagen-derived cancer medicines such as Padcev, plus Comirnaty and Paxlovid. Most revenue comes from the United States, with products sold across international markets.

Combines internal research with licensing, partnerships and acquisitions, then uses a global clinical, manufacturing and commercial network to move therapies from trials into regulated markets. Biopharma is the sole reportable segment; Pfizer CentreOne also provides contract development, manufacturing and specialty active ingredients. Revenue depends on regulatory approvals, payer access, successful clinical programs and patent protection, while several established medicines face generic or biosimilar competition as exclusivity expires.

Company facts

CEOAlbert Bourla
ListedJun 22, 1942
ExchangeNYSE
HeadquartersNew York City, NY
CountryUnited States
Employees75,000
CIK0000078003
ISINUS7170811035

Categories

Key statistics

Market cap$159.36B
EPS (ttm)$0.7568
P/E (ttm)36.95
ROE4.9%
P/B1.87
P/S2.50
Dividend yield6.15%
Beta0.33vs XLV 0.87

Year to date +11.0% · Average volume (30d) 37.3M

Analysts

Price target, next 12 months$27.50−1.6%Median of 39 analysts · vs the Aug 28 close
ConsensusHold15 of 39 analysts rate it buy or better

Ratings

Target range

Latest analyst notes

DateFirmActionPrior ratingRatingPrior targetTarget
Aug 7, 2026GuggenheimReiterateBuy$35$31
Jul 6, 2026HSBCDowngradeBuyHold$29$28
Jun 10, 2026RBC CapitalUpgradeUnderperformSector Perform
May 27, 2026UBSTarget$25$27
May 14, 2026Wolfe ResearchTarget$24$26

Earnings

EPS

Estimate$0.79
ReportedDue Nov 3, 2026

Revenue

Estimate$15.93B
ReportedDue Nov 3, 2026

History

Report dateEPS estEPSSurpriseRevenue estRevenueSurpriseNext session
Aug 4, 2026Q2 FY26$0.68$0.77+12.9%$14.40B$15.03B+4.4%+1.52%
May 5, 2026Q1 FY26$0.72$0.75+3.9%$13.84B$14.45B+4.4%+0.30%
Feb 3, 2026Q4 FY25$0.57$0.66+16.4%$16.85B$17.56B+4.2%+3.92%
Nov 4, 2025Q3 FY25$0.63$0.87+37.4%$16.50B$16.65B+0.9%+1.28%
View details

Financial highlights

12 quartersQ1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26
Revenue$13.72B$14.65B$16.65B$17.56B$14.45B$15.03B
Gross profit$9.83B$9.42B$12.48B$12.29B$9.72B$10.94B
Operating income$4.62B$3.58B$3.55B$3.69B$4.03B$4.71B
Net income$2.97B$2.91B$3.54B−$1.65B$2.69B−$246.0M
Diluted EPS$0.52$0.51$0.62−$0.29$0.47−$0.04
Gross margin71.7%64.3%74.9%70.0%67.3%72.8%
Operating margin33.7%24.4%21.3%21.0%27.9%31.3%

Fiscal years (4-quarter sums)FY21 $81.29B · FY22 $100.33B · FY23 $59.55B · FY24 $63.63B · FY25 $62.58B

Revenue by product · Q2 FY26

Biopharma Segment$14.66B · 98%
Segment Reporting, Reconciling Item, Corporate Nonsegment$373.0M · 2%

Revenue by geography · Q2 FY26

United States$8.86B · 59%
Developed Rest Of World$3.74B · 25%
Emerging Markets$2.43B · 16%

Balance sheet, Jun 28, 2026Cash & short-term investments $11.70B · Total debt $63.19B · Total assets $201.13B · Shareholders' equity $85.19B

Dividends

Next ex-date
Oct 24, 2026
estimated · in 56 days
Annual dividend
$1.72
per share
Dividend yield
6.15%
Schedule
Quarterly
4 payments a year

Raised for 16 straight years — most recently to $0.43 from $0.42 in Jan 2025. To collect a payout, hold shares through the close before the ex-date.

History

Ex-dateRecordPaidAmountNote
Jul 24, 2026Jul 24Sep 1$0.43
May 8, 2026May 8Jun 12$0.43
Jan 23, 2026Jan 23Mar 6$0.43
Nov 7, 2025Nov 7Dec 1$0.43
Jul 25, 2025Jul 25Sep 2$0.43
May 9, 2025May 9Jun 13$0.43
Jan 24, 2025Jan 24Mar 7$0.43raised from $0.42
Nov 8, 2024Nov 8Dec 2$0.42
View details

Ownership

Institutions 71.54%4.08B sharesInsiders 0.02%1.40M sharesOther 28.44%1.62B shares

Shares outstanding 5.70B · Float 5.69B · 99.9% free float

Top shareholders13F · 13D/G · Form 4

HolderShares% outstandingFormFiled
BlackRock, Inc.529.67M9.29%13FAug 7, 2026
Vanguard Capital Management LLC372.15M6.53%13FAug 13, 2026
State Street Corp307.09M5.39%13FAug 7, 2026
Geode Capital Management, LLC135.28M2.37%13FAug 12, 2026
Vanguard Portfolio Management LLC119.24M2.09%13FAug 13, 2026

Insider tradesForm 4

DateInsiderRoleSharesAvg price
Aug 12, 2026Albert Bourladirector, officer: Chairman & CEO+38,000$26.34
Aug 5, 2026Jennifer B. Damicoofficer: SVP & Controller−3,278$25.40
Aug 5, 2026Mortimer J. Buckleydirector+37,632$25.52
Aug 5, 2026Ronald E. Blaylockdirector+39,231$25.46
Jun 9, 2026Jennifer B. Damicoofficer: SVP & Controller−2,000$25.70
View details

Peers

  • Merck

    Keytruda oncology giant competing in cancer immunotherapy and adult vaccines.

  • Eli Lilly

    Dominant GLP-1 obesity/diabetes leader; defines the market Pfizer's Metsera must enter.

  • Novo Nordisk (ADR)

    GLP-1 obesity pioneer; conducted a direct Metsera bidding war against Pfizer in 2025.

  • AstraZeneca (ADR)

    ADC market leader via Enhertu; oncology share overlaps Pfizer's Seagen portfolio.

  • AbbVie

    Head-to-head in CGRP migraine; three-drug franchise spans acute, episodic, chronic.

  • Bristol-Myers Squibb

    Eliquis commercial partner and oncology rival via Opdivo in immuno-oncology.

  • GSK (ADR)

    Vaccine competitor in RSV (Arexvy vs Abrysvo) and adult immunization broadly.

  • Moderna

    Sole direct mRNA COVID vaccine rival; Spikevax competes with Comirnaty.

CompareAfter-hours close

CompanyPriceChange
Pfizer$27.95−0.04%$159.36B36.910.02.5+2.6%
Merck$148.19−0.08%$366.18B118.717.25.5+5.1%
Eli Lilly$1,173.00−0.08%$1.10T39.428.713.9+47.7%
Novo Nordisk (ADR)$45.60+0.00%$202.54B11.218.44.0+0.0%
AstraZeneca (ADR)$161.79−0.55%$252.33B24.415.24.1+6.4%
AbbVie$255.80+0.13%$451.38B72.016.87.0+10.2%
Bristol-Myers Squibb$66.60+0.05%$136.00B14.710.52.8+5.7%
GSK (ADR)$50.57−0.51%$101.82B15.89.22.2+2.7%
Moderna$136.53−1.06%$54.75B——24.6+2.1%
Median24.416.84.8+5.4%